Bortezomib Inhibits Osteoclastogenesis and Porphyromonas gingivalis Lipopolysaccharide-induced Alveolar Bone Resorption

Bortezomib enhances the osteogenic differentiation capacity of human mesenchymal stromal cells derived from bone marrow and placental tissues

(2014) Tanwarat Sanvoranart et al.   BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS

Bortezomib inhibits C2C12 growth by inducing cell cycle arrest and apoptosis

(2014) S.S. Xing et al.   BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS

Effects of the proteasome inhibitor, bortezomib, on cytodifferentiation and mineralization of periodontal ligament cells

(2014) J. Kitagaki et al.   JOURNAL OF PERIODONTAL RESEARCH

The effects of bortezomib on bone disease in patients with multiple myeloma

(2013) Mohamad Mohty et al.   CANCER

The proteasome inhibitor bortezomib stimulates osteoblastic differentiation of human osteoblast precursors via upregulation of vitamin D receptor signalling

(2013) Martin F. Kaiser et al.   EUROPEAN JOURNAL OF HAEMATOLOGY

Bortezomib induces apoptosis and autophagy in osteosarcoma cells through mitogen-activated protein kinase pathway in vitro

(2013) Zhiyuan Lou et al.   JOURNAL OF INTERNATIONAL MEDICAL RESEARCH

Impact of bortezomib on bone health in myeloma: A review of current evidence

(2012) Maurizio Zangari et al.   CANCER TREATMENT REVIEWS

Regulation of osteoblastic differentiation by the proteasome inhibitor bortezomib

(2012) Maki Uyama et al.   GENES TO CELLS

Protection Against Titanium Particle-Induced Inflammatory Osteolysis by the Proteasome Inhibitor Bortezomib In Vivo

(2012) Xin Mao et al.   INFLAMMATION

Bisphosphonate osteonecrosis of the jaw: A historical and contemporary review

(2011) Niall M.H. McLeod et al.   SURGEON-JOURNAL OF THE ROYAL COLLEGES OF SURGEONS OF EDINBURGH AND IRELAND

Proteasome inhibition aggravates tumor necrosis factor-mediated bone resorption in a mouse model of inflammatory arthritis

(2010) Karin Polzer et al.   ARTHRITIS AND RHEUMATISM

Bortezomib induces osteoblast differentiation via Wnt-independent activation of  -catenin/TCF signaling

(2009) Y.-W. Qiang et al.   BLOOD

Ca2+-NFATc1 signaling is an essential axis of osteoclast differentiation

(2009) Takako Negishi-Koga et al.   IMMUNOLOGICAL REVIEWS

The proteasome inhibitor, bortezomib suppresses primary myeloma and stimulates bone formation in myelomatous and nonmyelomatous bones in vivo

(2008) Angela Pennisi et al.   AMERICAN JOURNAL OF HEMATOLOGY

Pulse treatment with the proteasome inhibitor bortezomib inhibits osteoclast resorptive activity in clinically relevant conditions

(2008) P. Boissy et al.   LEUKEMIA RESEARCH

Bortezomib inhibits maturation and function of osteoclasts from PBMCs of patients with multiple myeloma by downregulating TRAF6

(2008) Huang Hongming et al.   LEUKEMIA RESEARCH